Order Article Reprints

Sreekumar S, Montaudon E, Klein D, Gonzalez ME, Painsec P, Derrien H, Sourd L, Smeal T, Marangoni E, Ridinger M. PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights. Cancers. 2024; 16(19):3259. https://doi.org/10.3390/cancers16193259

Sreekumar, Sreeja, Elodie Montaudon, Davis Klein, Migdalia E. Gonzalez, Pierre Painsec, Héloise Derrien, Laura Sourd, Tod Smeal, Elisabetta Marangoni, and Maya Ridinger. 2024. "PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights" Cancers 16, no. 19: 3259. https://doi.org/10.3390/cancers16193259

Sreekumar, S., Montaudon, E., Klein, D., Gonzalez, M. E., Painsec, P., Derrien, H., Sourd, L., Smeal, T., Marangoni, E., & Ridinger, M. (2024). PLK1 Inhibitor Onvansertib Enhances the Efficacy of Alpelisib in PIK3CA-Mutated HR-Positive Breast Cancer Resistant to Palbociclib and Endocrine Therapy: Preclinical Insights. Cancers, 16(19), 3259. https://doi.org/10.3390/cancers16193259